Alison Betts

TL;DR: A platform P BPK model has been developed that can not only simultaneously characterize mAb disposition data obtained from various previously published mouse PBPK models but is also capable of characterizing m Ab disposition in various preclinical species and human.

TL;DR: The use of ABC to infer tissue concentrations of mAbs and related molecules provides a valuable tool for investigating preclinical or clinical disposition of these molecules and it can also help eliminate or optimize biodistribution studies, and interpret efficacy or toxicity of the drug in a particular tissue.

TL;DR: A first of its kind mechanistic model has been developed for ADCs, which can integrate preclinical biomeasures and PK/PD data, to predict clinical response.

TL;DR: The authors demonstrated the effectiveness of this therapy in mouse models of several tumor types and confirmed that it reduces tumor-initiating cells and outperforms standard chemotherapy, and also had some unexpected benefits, reducing tumor angiogenesis and promoting antitumor immunity.

TL;DR: It was concluded that the calculation of MABEL according to the TMDD model was the most appropriate means for ensuring safety and efficacy in clinical studies.